Compare Amylx Pharmaceuticals Inc (AMLX) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Alliant Energy Corporation trades at $70.15 (market cap $17.78B). The key difference: Alliant Energy Corporation is far larger — about 6.7× Amylx Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 3.12% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LNT | |
|---|---|---|
Market Cap | $2.64B | $17.78B |
Sector | Health | Utilities |
52-Week High | $24.19 | $78.03 |
52-Week Low | $7.82 | $63.62 |
Enterprise Value | $2.39B | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
LNT trades at $70.25, up 2.98% today, with a bearish technical signal but strong fundamentals including a P/E of 21.7 and net income margin of 18.45%. Recent Q2 2026 earnings of $0.65 per share missed some estimates but beat others, with revenue growth supported by data center demand. The stock is near support at $68, with analyst consensus bullish and a $77.67 price target.
Outlook is positive due to consistent earnings beats, dividend yield, and institutional interest, but risks include high debt levels and competitive pressures. Investors may find value in its stable cash flow and growth in utility demand, though technical weakness suggests cautious entry near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
